Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma
- 136 Downloads
Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) α for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). We investigated the pretreatment predictive factors of early response, time to progression (TTP), and survival in response to intraarterial 5-FU/IFN combination therapy.
Patients with nonresectable HCC and variable PVTT grades (without PVTT to PVTT in the trunk) received intraarterial 5-FU/IFN combination therapy (n = 55).
After two courses of the combination therapy, 1 (2%), 15 (27%), 16 (29%), 12 (22%), and 11 (20%) of 55 patients showed complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or had dropped out (DO), respectively, when their early response to treatment was assessed. Univariate analysis identified only hepatitis C virus (HCV) antibody positivity as having significantly influenced the early response (P = 0.028) and TTP (P = 0.021). Multivariate analysis identified performance status (P = 0.003) and HCV antibody positivity (P = 0.007) as significant and independent determinants of survival. PVTT grade did not influence early response, TTP, or survival. The survival rate was significantly higher in patients who achieved CR or PR than in those that assessed as SD or PD, or DO (P < 0.0001, each).
HCV antibody positivity may be a significant pretreatment predictor of early response, TTP, and survival of patients with advanced HCC treated with 5-FU/IFN. CR or PR as the early response to the combination therapy might indicate a more favorable prognosis in patients with advanced HCC. PVTT grade did not seem to influence the efficacy of combination therapy.
Key wordsadvanced hepatocellular carcinoma 5-fluorouracil and interferon early response survival HCV
Unable to display preview. Download preview PDF.
- 3.Health and Welfare Statistics Association2000Health and welfare statisticsJ Health Welfare Stat47421Google Scholar
- 7.Kamada, K, Kitamoto, M, Aikata, H, Kawakami, Y, Kono, H, Imamura, M, et al. 2002Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinomaAm J Surg18428490PubMedCrossRefGoogle Scholar
- 14.Urabe, T, Kaneko, S, Matsushita, E, Unoura, M, Kobayashi, K 1998Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin, and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinomaOncology553947PubMedCrossRefGoogle Scholar
- 16.Ota, H, Nagano, H, Sakon, M, Eguchi, H, Kondo, M, Yamamoto, T, et al. 2005Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil: role of type I interferon receptor expressionBr J Cancer9355764PubMedCrossRefGoogle Scholar
- 18.Liver Cancer Study Group of Japan2000The general rules for the clinical and pathological study of primary liver cancer (in Japanese)4th edKaneharaTokyo19Google Scholar
- 20.Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, et al. Similar effects of recombinant IFN alpha-2b and natural IFN alpha when combined with intraarterial 5-fluorouracil for the treatment of advanced HCC. Liver Int (in press)Google Scholar
- 22.NCI Common Toxicity Criteria. http://ctep.cancer.gov/reporting/ctc.htmlGoogle Scholar
- 28.Someya, T, Ikeda, K, Saitoh, S, Kobayashi, M, Hosaka, T, Sezaki, H, et al. 2006Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosisJ Gastroenterol41120613PubMedCrossRefGoogle Scholar